Pfizer Corporation

Kevin Paul Girard

Peter Robert Rose

Douglas James Critcher

Yong Tao

Kris Nicole Jones

Andrew James Jensen

Gregory Scott Goeken

Brian Matthew Samas

David Sydney Bernard Daniels

The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof. The present invention also discloses a novel phosphoric acid salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharma-ceutical composition containing the same, as well as preparations and uses thereof.

Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto

The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.

Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole

Growing community of inventors

Quaker Hill, CT, United States of America

Kevin Paul Girard